|
Einstein scientists discover cause and possible treatments for hereditary movement disorder
March 02, 2006Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered the underlying cause of a type of ataxia, hereditary disorders characterized by poor balance, loss of posture and difficulty performing rapid coordinated movement. Their work also led to a drug that significantly improved the motor coordination in mice with ataxia-a finding that could lead to better therapies for the disease. The study appears in the March issue of Nature Neuroscience and was featured in the publication's advance online edition.
The research, led by Dr. Kamran Khodakhah, associate professor in the department of neuroscience at Einstein, focused on a type of ataxia called episodic ataxia type-2. It results from gene mutations that affect calcium channels, which are involved in releasing neurotransmitters in the brain and regulating excitability in neurons. Episodic ataxia type-2 was thought to be due to impaired transmission of neurotransmitters, but the Einstein scientists suspected that something else was going on.
They studied specialized cells in the brain's cerebellum called Purkinje cells, which are rich in calcium channels. Purkinje cells help coordinate movement by acting as information clearinghouses: They take in sensory and other inputs relayed to them by more than 150,000 excitatory and inhibitory synaptic inputs, combine them with the cello's own intrinsic activity or "pacemaking," and then send out the signals necessary for motor coordination.
The researchers investigated whether ataxia might be due to a reduction in the precision of the intrinsic pacemaking by Purkinje cells. Studying a number of mouse models of ataxia type-2, they found a gene-dependent loss of the precision of pacemaking in Purkinje cells, which prevented them from accurately accounting for the strength and timing of synaptic inputs when sending out signals directing muscle movement.
This loss of pacemaking precision was traced to reduced activity of calcium-activated potassium channels in Purkinje cells - a direct consequence of the reduced activity of calcium channels in these disorders. Einstein researchers were able to remedy this problem with a drug called 1-ethyl-2-benzimidazolinone (EBIO). When EBIO was infused into the brains of ataxic mice, the mice's motor coordination improved significantly.
"These calcium-activated potassium channels proved to be a potent therapeutic target, since chronically activating them with EBIO definitely improved the motor performance of these ataxic mice," says Dr. Khodakhah, who was senior author of the study. "We don't really have effective treatments for these types of ataxia, so we're hopeful that our findings will lead to drugs that will improve the lives of people with this condition."
Dr Khodakhah has established collaborations with two neurologists, Dr Joanna Jen (UCLA) and Dr Michael Strupp (Germany) to explore the potential use of similar drugs in patients. The other Einstein researchers involved in the study were Joy T. Walter, Karina Alvina, Mary D. Womack and Carolyn Chevez.
Albert Einstein College of Medicine
The researchers investigated whether ataxia might be due to a reduction in the precision of the intrinsic pacemaking by Purkinje cells. Studying a number of mouse models of ataxia type-2, they found a gene-dependent loss of the precision of pacemaking in Purkinje cells, which prevented them from accurately accounting for the strength and timing of synaptic inputs when sending out signals directing muscle movement.
This loss of pacemaking precision was traced to reduced activity of calcium-activated potassium channels in Purkinje cells - a direct consequence of the reduced activity of calcium channels in these disorders. Einstein researchers were able to remedy this problem with a drug called 1-ethyl-2-benzimidazolinone (EBIO). When EBIO was infused into the brains of ataxic mice, the mice's motor coordination improved significantly.
"These calcium-activated potassium channels proved to be a potent therapeutic target, since chronically activating them with EBIO definitely improved the motor performance of these ataxic mice," says Dr. Khodakhah, who was senior author of the study. "We don't really have effective treatments for these types of ataxia, so we're hopeful that our findings will lead to drugs that will improve the lives of people with this condition."
Dr Khodakhah has established collaborations with two neurologists, Dr Joanna Jen (UCLA) and Dr Michael Strupp (Germany) to explore the potential use of similar drugs in patients. The other Einstein researchers involved in the study were Joy T. Walter, Karina Alvina, Mary D. Womack and Carolyn Chevez.
Albert Einstein College of Medicine
Ataxia News and Current Ataxia Events RSSMolecular basis for neurodegeneration in Ataxia telangiectasia
An upcoming paper from Dr. David Wassarman (University of Wisconsin School of Medicine and Public Health) in the May 1 issue of G&D lends new insight into the pathogenesis of neurodegeneration in Ataxia telangiectasia.
Chicken pox vaccination should be introduced for children in the UK
The only realistic way of preventing deaths and severe complications arising from chickenpox is to routinely vaccinate children against the disease, concludes research published ahead of print in Archives of Disease in Childhood.
Researchers identify proteins involved in new neurodegenerative syndrome
The interplay of two proteins that bind to messenger RNA, a molecule that mediates translation of the information encoded in genes into proteins, triggers the appearance of fragile X-associated tremor/ataxia syndrome (FTAX), a late-life disorder associated with the gene that causes fragile X syndrome in children.
Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
Scientists have discovered a key protein in the toxic brain pathway that leads to fragile X tremor/ataxia syndrome (FXTAS), an inherited neurodegenerative disorder.
Protein 'chatter' linked to cancer activation
Scientists have found the existence of cross-talk between human chromosome ends and the protein complexes central to the stability of the entire human genome, a "chat" that contributes to cancer development.
Scientists Discover Role of Enzyme in DNA Repair
Scientists from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Cancer Institute (NCI), and Integrative Bioinformatics Inc. have made an important discovery about the role of an enzyme called ataxia telangiectasia mutated protein (ATM) in the body's ability to repair damaged DNA. NIAMS and NCI are part of the National Institutes of Health (NIH).
DNA repair proteins monitored at double-strand break
Investigators at St. Jude Children's Research Hospital had a molecule's eye view of the human cell's DNA repair kit as it assembled on a double-strand break to link together the broken ends.
Moonlighting enzyme linked to neurodegenerative disease
Friedreich's ataxia is one of those diseases few have heard of unless you know someone with the condition. For that individual -- usually a child or teenager -- it is devastating.
Mutant gene shatters nerves
If you bend a knee or an elbow, the nerves in your limbs stretch but do not break. A University of Utah study suggests why: A gene produces a springy protein that keeps nerve cells flexible. When the gene was disabled in tiny nematode worms, their nerve cells literally broke.
U of MN researchers link early brain development to adult-onset neurodegenerative disease
Researchers at the University of Minnesota's Institute for Human Genetics have shown for the first time that the severity of an adult neurodegenerative disease is tied to how well the brain developed shortly after birth.
More Ataxia News Articles
| © 2008 BrightSurf.com |